The licensed patents result from the research of James Thompson of the University of Wisconsin Stem Cell and Regenerative Medicine Center and director of regenerative biology at the new Morgridge Institute for Research.
The license is expected to accelerate VistaGen’s commercial programs focused on providing customized, next-generation, stem cell-based predictive toxicology and drug discovery screening assays to increase preclinical R&D productivity for the pharmaceutical industry.
Ralph Snodgrass, CEO of VistaGen, said: “This agreement with Wisconsin Alumni Research Foundation (WARF) is another critical step in our strategy to become ‘one-stop-shop’ for the world’s premier stem cell differentiation systems. It enhances our fundamental expertise for capturing the value of human embryonic stem cell biology for predictive toxicology, drug discovery screening and drug development.”